Nunzia Pharmaceutical (NUNZ) 10-Q 16 Sep 21 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Sep. 10, 2021
Details
Registrant CIK	0000886093
Fiscal Year End	--12-31
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	000-22744
Entity Registrant Name	NUNZIA PHARMACEUTICAL COMPANY
Entity Incorporation, State or Country Code	UT
Entity Tax Identification Number	87-0442090
Entity Address, Address Line One	1627 West 14th Street
Entity Address, City or Town	Long Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90813
City Area Code	714
Local Phone Number	609-9117
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		256,119,578
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2020	Dec. 31, 2019
ASSETS
Total assets	$ 0	$ 0
Current liabilities
Accounts payable and accrued liabilities	21,442	21,333
Related party advances	5,536	1,242
Total current liabilities	26,978	22,575
Stockholders' deficit
Common stock payable	50,000	50,000
Additional paid-in capital	29,134	26,886
Retained deficit	(340,933)	(334,032)
Total stockholders' deficit	(26,978)	(22,575)
Total liabilities and stockholders' deficit	0	0
Common Class A
Stockholders' deficit
Common Stock, Value, Issued	234,770	234,520
Common Class B
Stockholders' deficit
Common Stock, Value, Issued	$ 51	$ 51

CONSOLIDATED BALANCE SHEETS - P

CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Common Class A
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Shares, Issued	234,769,578	234,519,578
Common Stock, Shares, Outstanding	234,769,578	234,519,578
Common Class B
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000	100,000
Common Stock, Shares, Issued	51,000	51,000
Common Stock, Shares, Outstanding	51,000	51,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Details
Revenues	$ 0	$ 0
Operating expense
General and Administrative Expense	6,901	6,257
Total operating expense	6,901	6,257
Loss from operations	(6,901)	(6,257)
Net loss	$ (6,901)	$ (6,257)
Basic and Diluted Loss per Common Share	$ 0	$ 0
Weighted average number of common shares outstanding - basic and diluted	284,778,797	250,073,035

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)	Common Stock Payable	Additional Paid-in Capital	Retained Earnings	Total	Common Class A	Common Class B
Equity Balance at Dec. 31, 2018	$ 50,000	$ (243,643)	$ (300,397)	$ (293,967)	$ 200,022	$ 51
Equity Balance, Shares at Dec. 31, 2018					200,022,035	51,000
Net loss	0	0	(6,257)	(6,257)	$ 0	$ 0
Equity Balance, Shares at Mar. 31, 2019					200,022,035	51,000
Equity Balance at Mar. 31, 2019	50,000	(243,643)	(300,397)	(300,224)	$ 200,022	$ 51
Equity Balance at Dec. 31, 2019	50,000	26,886	(334,032)	(22,575)	$ 234,520	$ 51
Equity Balance, Shares at Dec. 31, 2019					234,519,578	51,000
Common stock issued for services	0	2,248	0	2,498	$ 250	$ 0
Common stock issued for services					250,000
Net loss	0	0	(6,901)	(6,901)	$ 0	$ 0
Equity Balance, Shares at Mar. 31, 2020					234,769,578	51,000
Equity Balance at Mar. 31, 2020	$ 50,000	$ 29,134	$ (340,933)	$ (26,978)	$ 234,770	$ 51

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities
Net loss	$ (6,901)	$ (6,257)
Adjustments to reconcile net loss to net cash flows from operating activities
Stock based compensation expense	2,498	0
Changes in operating assets and liabilities:
Increase (decrease) in accounts payable and accrued expenses	109	807
Increase in related party advances	4,294	5,450
Net cash flows from operating activities	0	0
Change in cash	0	0
Cash at beginning of period	0	0
Cash at end of period	0	0
Supplemental disclosure of cash flow information:
Interest paid in cash	0	0
Income taxes paid in cash	0	0
Supplemental disclosure of non-cash transactions:
Common stock issued as payment for liabilities	$ 2,498	$ 0

NOTE 1 -Basis of Presentation,

NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements	NOTE 1 –Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements Basis of Presentation The accompanying unaudited interim consolidated financial statements of Nunzia Pharmaceutical Company (the “ Company The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. In the opinion of management, the accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company’s financial position as of March 31, 2020, results of operations for the three months ended March 31, 2020 and 2019, and stockholders equity and cash flows for the three months ended March 31, 2020 and 2019. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year. Organization Our Company’s name is Nunzia Pharmaceutical Company. The Company was incorporated on November 12, 1986. On February 1, 2018, the Company amended its Articles of Incorporation to change its name to Nunzia Pharmaceutical Corporation. On October 22, 2017, the Company and Cal-Biotech, Inc. (“ Cal-Biotech MCA MCA Shares LionsGate Prior to the close of the MCA, LionsGate held a majority beneficial ownership interest in the Company and Cal-Biotech. Thus, due to the common control of the Company and Cal-Biotech, pursuant to ASC 805-50-25, “Transactions Between Entities Under Common Control”, the MCA was accounted for as a transfer of the carrying amounts of assets and liabilities under the predecessor value method of accounting. The predecessor values method of accounting requires the receiving entity (i.e., the Company) to report the results of operations as if both entities had been combined as of the beginning of the periods presented. The consolidated financial statements above include both entities’ full results, including the financial statements of Cal-Biotech since inception on February 7, 2018. Going Concern The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $340,933) The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds and funds from the sale of shares of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying financial statements. Recent accounting pronouncements not yet adopted In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes. The guidance removes certain exceptions for recognizing deferred taxes for equity method investments, performing intra period allocation, and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for goodwill and allocating taxes to members of a consolidated group, among others. This guidance is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The transition requirements are dependent upon each amendment within this update and will be applied either prospectively or retrospectively. The adoption of ASU 2019-12 is not expected to have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. Recently adopted accounting pronouncements The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the consolidated financial statements.

NOTE 2 - Preferred and Common S

NOTE 2 - Preferred and Common Stock	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 2 - Preferred and Common Stock	NOTE 2 – Preferred and Common Stock Preferred Stock The Company has Preferred stock: $1.00 par value; 50,000,000 shares authorized with no shares issued and outstanding. Common Stock The Company has 51,000 shares of Class B Common Stock issued and outstanding as of March 31, 2020. The Class B shares are the only shares eligible to vote for Directors. LionsGate holds all Class B common shares. The Company has 1,000,000,000 shares of Class A Common Stock authorized of which 234,769,578 and 234,519,578 shares are issued and outstanding as of March 31, 2020 and December 31, 2019, respectively. 50,000,000 MCA Shares due to LionsGate have not been issued as of March 31, 2020 and 31,650,000 MCA Shares due to LionsGate have not been issued as of the date of this report. On January 15, 2020, the Company issued 250,000 shares of class A common stock to a vendor in exchange for services for which the Company carried a balance in Accounts Payable of $2,498 as of December 31, 2019. On December 4, 2019, the Company affected a 1-for-7,000 reverse stock split reducing the number of shares outstanding from 126,859,077 to 19,578. All per share amounts have been adjusted to reflect the split.

NOTE 3 - Commitments and Contin

NOTE 3 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 3 - Commitments and Contingencies	NOTE 3 – Commitments and Contingencies COVID-19 In December 2019, an outbreak of the COVID-19 virus was reported in Wuhan, China. On March 11, 2020, the World Health Organization declared the COVID-19 virus a global pandemic and on March 13, 2020, President Donald J. Trump declared the virus a national emergency in the United States. This highly contagious disease has spread to most of the countries in the world and throughout the United States, creating a serious impact on customers, workforces and suppliers, disrupting economies and financial markets, and potentially leading to a world-wide economic downturn. It has caused a disruption of the normal operations of many businesses, including the temporary closure or scale-back of business operations and/or the imposition of either quarantine or remote work or meeting requirements for employees, either by government order or on a voluntary basis. The pandemic may adversely affect our operations, our employees and our employee productivity. It may also impact the ability of our subcontractors, partners, and suppliers to operate and fulfill their contractual obligations, and result in an increase in costs, delays or disruptions in performance. Our employees are working remotely and using various technologies to perform their functions. In reaction to the spread of COVID-19 in the United States, many businesses have instituted social distancing policies, including the closure of offices and worksites and deferring planned business activity. The disruption and volatility in the global and domestic capital markets may increase the cost of capital and limit our ability to access capital. Both the health and economic aspects of the COVID-19 virus are highly fluid and the future course of each is uncertain. For these reasons and other reasons that may come to light if the coronavirus pandemic and associated protective or preventative measures expand, we may experience a material adverse effect on our business operations, revenues and financial condition; however, its ultimate impact is highly uncertain and subject to change.

NOTE 4 - Transactions with Rela

NOTE 4 - Transactions with Related Persons	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 4 - Transactions with Related Persons	NOTE 4 – Transactions with Related Persons From time-to-time, Mr. Michael Mitsunaga, our President and Director, and Lionsgate, directly in 2020 and through its subsidiary, Cal-Biotech in 2019, make non-interest-bearing advances to the Company. Such advances totaled $4,294 and $5,450 during the three months ended March 31, 2020 and 2019, respectively.

NOTE 5 - Subsequent Events

NOTE 5 - Subsequent Events	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 5 - Subsequent Events	NOTE 5 – Subsequent Events Management has reviewed material events subsequent of the period ended March 31, 2020 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”. On August 16, 2020, the Board issued 9.6 million of the MCA shares. On December 21, 2020, the Company entered into a License Agreement (the “ License Agreement On April 12, 2021, the Company and Global WholeHealth Partners Corp. (“Global”) entered into a Mutual Sales and Marketing Agreement (the “MSMA”). Pursuant to the terms of the MSMA, each company has mutual abilities to share their products for sale under nonexclusive but favorable conditions and prices. The duration of the agreement is for an initial period of five years commencing on April 12, 2021. As consideration for the MSMA, the Company agreed to issue 5,000,000 shares of its restricted common stock to Global and Global agreed to issue 5,000,000 shares of its restricted common stock to the Company. The Company received the Global shares on April 22, 2021. The companies are considered related parties as they share the same CEO and significant shareholder, LionsGate. On April 26, 2021, the Company issued 17,750,000 MCA Shares and on June 7, 2021, 9,000,000 MCA Shares originally issued in error on August 16, 2020, were returned to the Company bringing the total unissued MCA Shares to 31,650,000. On June 7, 2021, 9,000,000 shares of MCA Class A common stock originally issued in error on August 16, 2020, were returned to the Company.

NOTE 1 -Basis of Presentation_2

NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited interim consolidated financial statements of Nunzia Pharmaceutical Company (the “ Company The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results may differ from those estimates. In the opinion of management, the accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company’s financial position as of March 31, 2020, results of operations for the three months ended March 31, 2020 and 2019, and stockholders equity and cash flows for the three months ended March 31, 2020 and 2019. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

NOTE 1 -Basis of Presentation_3

NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Organization (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Organization	Organization Our Company’s name is Nunzia Pharmaceutical Company. The Company was incorporated on November 12, 1986. On February 1, 2018, the Company amended its Articles of Incorporation to change its name to Nunzia Pharmaceutical Corporation. On October 22, 2017, the Company and Cal-Biotech, Inc. (“ Cal-Biotech MCA MCA Shares LionsGate Prior to the close of the MCA, LionsGate held a majority beneficial ownership interest in the Company and Cal-Biotech. Thus, due to the common control of the Company and Cal-Biotech, pursuant to ASC 805-50-25, “Transactions Between Entities Under Common Control”, the MCA was accounted for as a transfer of the carrying amounts of assets and liabilities under the predecessor value method of accounting. The predecessor values method of accounting requires the receiving entity (i.e., the Company) to report the results of operations as if both entities had been combined as of the beginning of the periods presented. The consolidated financial statements above include both entities’ full results, including the financial statements of Cal-Biotech since inception on February 7, 2018.

NOTE 1 -Basis of Presentation_4

NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Going Concern (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Going Concern	Going Concern The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern. As of March 31, 2020, the Company had an accumulated deficit of $340,933) The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds and funds from the sale of shares of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying financial statements.

NOTE 1 -Basis of Presentation_5

NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Recent accounting pronouncements not yet adopted (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Recent accounting pronouncements not yet adopted	Recent accounting pronouncements not yet adopted In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes. The guidance removes certain exceptions for recognizing deferred taxes for equity method investments, performing intra period allocation, and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for goodwill and allocating taxes to members of a consolidated group, among others. This guidance is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The transition requirements are dependent upon each amendment within this update and will be applied either prospectively or retrospectively. The adoption of ASU 2019-12 is not expected to have a material impact on the Company’s consolidated financial position, results of operations, or cash flows.

NOTE 1 -Basis of Presentation_6

NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Recently adopted accounting pronouncements (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Recently adopted accounting pronouncements	Recently adopted accounting pronouncements The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion. The Company believes that none of the new standards will have a significant impact on the consolidated financial statements.

NOTE 1 -Basis of Presentation_7

NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Organization (Details) - USD ($)	Dec. 13, 2020	Feb. 01, 2018	Sep. 10, 2021	Mar. 31, 2020
Stockholders Equity Reverse Stock Split		7,000:1
Merger And Consolidation Agreement
Shares Unissued				50,000,000
Merger And Consolidation Agreement | Lions Gate - Majority Owner Of Cal Biotech
Shares Unissued				31,650,000
Subsequent Event | Merger And Consolidation Agreement
Shares Unissued	284,500,000		31,650,000
Subsequent Event | Merger And Consolidation Agreement | Lions Gate - Majority Owner Of Cal Biotech
Shares Issued In Exchange Of Debt Settlement	248,270,000
Debt Settlement	$ 156,657
Subsequent Event | Merger And Consolidation Agreement | Cal Biotech - Related And Non Related Parties
Shares Issued In Exchange Of Debt Settlement	36,230,000
Debt Settlement	$ 144,570

NOTE 1 -Basis of Presentation_8

NOTE 1 -Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements: Going Concern (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Details
Retained deficit	$ (340,933)	$ (334,032)

NOTE 2 - Preferred and Common_2

NOTE 2 - Preferred and Common Stock (Details) - USD ($)	Jan. 15, 2020	Dec. 04, 2019	Feb. 01, 2018	Mar. 31, 2020	Dec. 31, 2019
Stockholders Equity Reverse Stock Split			7,000:1
Merger And Consolidation Agreement
Shares Unissued				50,000,000
Merger And Consolidation Agreement | Lions Gate - Majority Owner Of Cal Biotech
Shares Unissued				31,650,000
Common Class B
Common Stock, Shares, Issued				51,000	51,000
Common Stock, Shares, Outstanding				51,000	51,000
Common Stock, Voting Rights				The Class B shares are the only shares eligible to vote for Directors. LionsGate holds all Class B common shares.
Common Stock, Shares Authorized				100,000	100,000
Common Class A
Common Stock, Shares, Issued				234,769,578	234,519,578
Common Stock, Shares, Outstanding				234,769,578	234,519,578
Common Stock, Shares Authorized				1,000,000,000	1,000,000,000
Common stock issued for services	250,000			250,000
Accounts Payable					$ 2,498
Preferred Stock
Preferred Stock, Par or Stated Value Per Share				$ 1
Preferred Stock, Shares Authorized				50,000,000
Common Stock
Stockholders Equity Reverse Stock Split		1-for-7,000
Stock Issued During Period, Shares, Reverse Stock Splits		126,859,077
Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares		19,578

NOTE 4 - Transactions with Re_2

NOTE 4 - Transactions with Related Persons (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Mr.Michael Mitsunaga, President And Director
Advances From Related Party	$ 4,294	$ 5,450

NOTE 5 - Subsequent Events (Det

NOTE 5 - Subsequent Events (Details) - USD ($)	Jun. 07, 2021	Apr. 12, 2021	Dec. 21, 2020	Sep. 10, 2021	Jul. 08, 2021	Apr. 26, 2021	Dec. 13, 2020	Aug. 16, 2020	Mar. 31, 2020
Merger And Consolidation Agreement
Shares Unissued									50,000,000
Subsequent Event | Merger And Consolidation Agreement
Shares Issued						17,750,000		9,600,000
Shares Unissued				31,650,000			284,500,000
Shares Returned	9,000,000
Subsequent Event Description	On June 7, 2021, 9,000,000 shares of MCA Class A common stock originally issued in error on August 16, 2020, were returned to the Company.
Subsequent Event | License Agreement With Michael Mitsunaga
Shares Issued					3,000,000
Agreement Description			The Company agreed to issue 3,000,000 shares of common stock and pay a 2% fee of gross sales. The duration of the Agreement is for an initial period of five years commencing on August 3, 2021.
Fee Of Gross Sales			2.00%
Shares Issued Date			Jul. 8, 2021
Share Issue Price Per Share			$ 3
Stock Issued Value			$ 9,000,000
Loss On Related Party Transfer Of Intangible Assets			$ 9,000,000
Subsequent Event | Mutual Sales And Marketing Agreement - Global Whole Helath Partners Corp
Agreement Description		On April 12, 2021, the Company and Global WholeHealth Partners Corp. (“Global”) entered into a Mutual Sales and Marketing Agreement (the “MSMA”). Pursuant to the terms of the MSMA, each company has mutual abilities to share their products for sale under nonexclusive but favorable conditions and prices. The duration of the agreement is for an initial period of five years commencing on April 12, 2021.
Shares Unissued		5,000,000
Subsequent Event | Global WholeHealth Partners Corp | Restricted Stock
Shares Unissued		5,000,000